HRP20150040T1 - Postupak lijeäśenja krvotvornih novotvorina - Google Patents

Postupak lijeäśenja krvotvornih novotvorina Download PDF

Info

Publication number
HRP20150040T1
HRP20150040T1 HRP20150040AT HRP20150040T HRP20150040T1 HR P20150040 T1 HRP20150040 T1 HR P20150040T1 HR P20150040A T HRP20150040A T HR P20150040AT HR P20150040 T HRP20150040 T HR P20150040T HR P20150040 T1 HRP20150040 T1 HR P20150040T1
Authority
HR
Croatia
Prior art keywords
compound
accordance
intended
cation
combretastatin
Prior art date
Application number
HRP20150040AT
Other languages
English (en)
Croatian (hr)
Inventor
David Chaplin
Bronwyn G. Siim
Original Assignee
Oxigene, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxigene, Inc. filed Critical Oxigene, Inc.
Publication of HRP20150040T1 publication Critical patent/HRP20150040T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
HRP20150040AT 2007-11-21 2008-11-21 Postupak lijeäśenja krvotvornih novotvorina HRP20150040T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98978607P 2007-11-21 2007-11-21
EP08851754.5A EP2219451B1 (en) 2007-11-21 2008-11-21 Method for treating hematopoietic neoplasms
PCT/US2008/084427 WO2009067706A1 (en) 2007-11-21 2008-11-21 Method for treating hematopoietic neoplasms

Publications (1)

Publication Number Publication Date
HRP20150040T1 true HRP20150040T1 (hr) 2015-02-27

Family

ID=40667883

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150040AT HRP20150040T1 (hr) 2007-11-21 2008-11-21 Postupak lijeäśenja krvotvornih novotvorina

Country Status (12)

Country Link
US (4) US20090192098A1 (enExample)
EP (1) EP2219451B1 (enExample)
JP (1) JP5302328B2 (enExample)
AU (1) AU2008326251B2 (enExample)
CA (1) CA2703283C (enExample)
DK (1) DK2219451T3 (enExample)
ES (1) ES2529434T3 (enExample)
HR (1) HRP20150040T1 (enExample)
PL (1) PL2219451T3 (enExample)
PT (1) PT2219451E (enExample)
SI (1) SI2219451T1 (enExample)
WO (1) WO2009067706A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070233391A1 (en) * 2002-03-07 2007-10-04 Cambridge University Technical Service Limited (CUTS) Scd fingerprints
EP2219451B1 (en) 2007-11-21 2014-11-12 Oxigene, Inc. Method for treating hematopoietic neoplasms
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
CN104276960B (zh) * 2014-09-26 2016-09-28 安徽省逸欣铭医药科技有限公司 盐酸他喷他多和塞来昔布共晶及其组合物和制备方法
EP3337495A4 (en) * 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
AU2018355886A1 (en) * 2017-10-25 2020-05-14 Bionomics Limited Method for treating acute myeloid leukemia
US20220096473A1 (en) * 2019-01-15 2022-03-31 Ptc Therapeutics, Inc. Method for treating an acute myeloid leukemia

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996237A (en) 1987-01-06 1991-02-26 Arizona Board Of Regents Combretastatin A-4
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
US4940726A (en) 1989-04-26 1990-07-10 Arizona Board Of Regents Cell growth inhibitory macrocyclic lactones denominated Combretastatin D-1 and Combretastatin D-2
GB9106177D0 (en) 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5430062A (en) 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5731353A (en) 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
WO1998042328A1 (en) 1997-03-26 1998-10-01 Biosource Technologies, Inc. Di-aryl ethers and their derivatives as anti-cancer agents
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
DE69942645D1 (en) 1998-01-09 2010-09-16 Body Corporate Of The State Of Synthese von combretastatin a-4 prodrugs
CA2314510A1 (en) 1998-01-09 1999-07-15 George R. Pettit Synthesis of phenstatin and prodrugs thereof
GB2334256A (en) 1998-02-12 1999-08-18 Univ Montfort Hydroxylation activated prodrugs
JP2002507567A (ja) 1998-03-25 2002-03-12 ラージ スケール バイオロジー コーポレイション 血管形成を阻害するための安息香酸誘導体
US6433012B1 (en) 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
CA2326761C (en) 1998-04-03 2008-02-19 Ajinomoto Co., Inc. Antitumor agent
AU5227999A (en) 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents
US6433187B1 (en) 1998-12-17 2002-08-13 Tularik Inc. Certain polycyclic compounds useful as tubulin-binding agents
GB9903403D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
EP2289521A3 (en) 1999-02-18 2011-10-05 Arizona Board Of Regents Compositions and methods for use in tergeting vascular destruction
CO5170498A1 (es) 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
US6201001B1 (en) 1999-08-02 2001-03-13 Abbott Laboratories Imidazole antiproliferative agents
GB9918912D0 (en) 1999-08-12 1999-10-13 Angiogene Pharm Ltd New stilbenes with vascular damaging activity
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
WO2001068654A2 (en) * 2000-03-10 2001-09-20 Baylor University Tubulin binding ligands and corresponding prodrug constructs
GB0007401D0 (en) 2000-03-27 2000-05-17 Cancer Res Campaign Tech Substituted chalcones as therapeeutic compounds
EP1299337A4 (en) 2000-04-27 2004-10-13 Univ Arizona State HYDROXYPHENSTATIN AND ITS PROMEDICATIONS
EP1278758B1 (en) * 2000-04-27 2011-10-05 ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA acting for and on behalf of ARIZONA STATE UNIVERSITY Combretastatin A-1 phosphate and Combretastatin B-1 phosphate prodrugs
CA2408220A1 (en) 2000-05-09 2001-11-15 George R. Pettit Antitubulin assembly and cell growth inhibitor denominated "dioxostatin"
DE60118571T2 (de) * 2000-05-15 2007-02-01 Celgene Corp. Pharmazeutische zusammensetzungen zur behandlung von krebs welche thalidomid und topoisomerase inhibitoren enthalten
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
AU2001296215A1 (en) * 2000-07-17 2002-01-30 Oxi-Gene, Inc. Efficient method of synthesizing combretastatin a-4 prodrugs
GB0019944D0 (en) 2000-08-15 2000-09-27 Angiogene Pharm Ltd Compositions with vascular damaging activity
US6670344B2 (en) 2000-09-14 2003-12-30 Bristol-Myers Squibb Company Combretastatin A-4 phosphate prodrug mono- and di-organic amine salts, mono- and di- amino acid salts, and mono- and di-amino acid ester salts
EP1351912A2 (en) 2000-12-21 2003-10-15 Cancer Research Ventures Limited Substituted stilbenes, their reactions and anticancer activity
US7037906B1 (en) 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
CA2432792C (en) * 2000-12-22 2012-04-03 Bristol-Myers Squibb Company Methods for modulating tumor growth and metastasis
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
GB2377469B (en) 2001-07-13 2005-07-06 Prismo Ltd Method and apparatus for laying a traffic calming surface
CA2463902A1 (en) 2001-10-26 2003-05-01 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents
GB0126889D0 (en) 2001-11-08 2002-01-02 Paterson Inst For Cancer Res Compounds and their uses
EP1465852A4 (en) 2001-12-21 2006-04-26 Univ Arizona SYNTHESIS OF PROMDERICAMENTS OF COMBRETASTATIN A-2
EP1515716A2 (en) 2002-04-03 2005-03-23 Astrazeneca AB Indole derivatives having anti-angiogenetic activity
US7358236B1 (en) * 2002-06-21 2008-04-15 Oxigene, Inc. Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents
US20040024696A1 (en) 2002-08-02 2004-02-05 Federico Alves System for automatically transferring funds
TW549690U (en) 2002-11-13 2003-08-21 Tekcon Electronics Corp Electrical card connector
US8198302B2 (en) 2003-02-28 2012-06-12 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
ITRM20030355A1 (it) 2003-07-18 2005-01-19 Sigma Tau Ind Farmaceuti Composti ad attivita' citotossica derivati della combretastatina.
ES2551086T3 (es) 2005-06-14 2015-11-16 Baylor University Análogos de combretastatina con actividad de unión a tubulina
EP2219451B1 (en) 2007-11-21 2014-11-12 Oxigene, Inc. Method for treating hematopoietic neoplasms

Also Published As

Publication number Publication date
EP2219451A1 (en) 2010-08-25
EP2219451B1 (en) 2014-11-12
CA2703283A1 (en) 2009-05-28
ES2529434T3 (es) 2015-02-20
AU2008326251B2 (en) 2014-03-06
SI2219451T1 (sl) 2015-02-27
PL2219451T3 (pl) 2015-04-30
US9040500B2 (en) 2015-05-26
US20090192098A1 (en) 2009-07-30
PT2219451E (pt) 2015-02-09
US20090264382A1 (en) 2009-10-22
EP2219451A4 (en) 2011-01-19
JP2011504510A (ja) 2011-02-10
DK2219451T3 (en) 2015-01-12
AU2008326251A1 (en) 2009-05-28
JP5302328B2 (ja) 2013-10-02
US20120270831A1 (en) 2012-10-25
US20150246064A1 (en) 2015-09-03
WO2009067706A1 (en) 2009-05-28
CA2703283C (en) 2016-01-12

Similar Documents

Publication Publication Date Title
HRP20150040T1 (hr) Postupak lijeäśenja krvotvornih novotvorina
ES2632002T3 (es) Intercambiador de presión
BR112014016840A2 (pt) conector de engate rápido para transferência de fluidos
AR093226A1 (es) Formas solidas de dihidrogeno fosfato de (r)-2-(5-(2-(3-etilureido)-6-fluoro-7-(tetrahidrofuran-2-il)-1h-benzo[d]imidazol-5-il)pirimidin-2-il)propan-2-ilo y sus sales
JP2013544617A5 (enExample)
RU2015145481A (ru) Устройство для обработки белья
ATE464001T1 (de) Endoskop
ATE498352T1 (de) Flächenspitzenanordnung für ein endoskop
BR112014003511A2 (pt) transferência de calor entre fluidos
EP2039018A4 (en) ESTIMATION OF TRANSMISSION LINE INSERTION LOSSES
ATE542469T1 (de) Diagnosekamera sowie aufsatz zur realisierung einer solchen
EP2212853A4 (en) VIRTUAL REALITY TOOLS FOR DEVELOPING INFECTION CONTROL SOLUTIONS
GEP20115335B (en) Methods of treating surfaces with ionic organosilicon compositions
AR063486A1 (es) Composicion adhesiva de silicona y metodo de preparacion de la misma
ES2531190T3 (es) Método para producir un compuesto de 4-oxoquinolina
AR070305A1 (es) Unidad de intercambio de calor para reactores quimicos isotermicos
EP2982732A4 (en) Flame retardant composition, flame retardant fiber having flame retardant composition and method for increasing the amount of a flame retardant component employing fiber based on the composition of this invention
BR112017018859A2 (pt) detergente para lavagem automática de louças
RU2017102503A (ru) Твердый смазочный материал для оцинкованной стали
MY166229A (en) Nonwoven fabric and textile treating agent
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
BR102017014724A8 (pt) Processos para a preparação de 4-alcóxi-3-(acil ou alquil)oxipicolinamidas
BR112015030112A2 (pt) dispositivo de retenção e máquina de chapeamento de alta velocidade dotada do mesmo
AR044801A1 (es) Sales de aminas del acido (2s)-2-etoxi-3-(4-{2-[hexil(2-feniletil)amino]-2-oxoetoxi}fenil)propanoico
EP2320727A4 (en) SALT, AQUEOUS LIQUID COMPOSITIONS CONTAINING SALT (S) OF S - (+) - ABCISINIC ACID, AND METHOD FOR THE PRODUCTION THEREOF